Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected Unit-III, a Formulation manufacturing facility, of Eugia Pharma Specialities, a wholly owned subsidiary of the Company, situated at Phase-III, TSIIC, EPIP, IDA, Pashamylaram, Patancheru Revenue Mandal, Sangareddy District, 502307, Telangana, from 27 January to 06 February 2026.

The inspection concluded with 11 observations. The observations are procedural in nature and will be responded to within the stipulated time.